OriGene社 Update on clinical trials using IDO1-inhibitors in cancer treatments
IDO1, also known as Indoleamine 2,3-Dioxygenase 1, encodes a heme enzyme involved in the oxidation of L-Tryptophan in the kynurenine (Kyn) pathway. The Kyn pathway is associated with immunosuppression and increased levels of IDO1 in the tumor microenvironment have been shown to weaken anti-tumor responses. Overexpression of IDO1 is commonly associated with poor prognosis in a variety of cancers including breast cancer, colorectal cancer, non-small cell lung cancer, esophageal cancer, and many others. IDO1 inhibitors have been developed in an attempt to prevent cancer immune escape and many are undergoing clinical trials. Tang et. al. publication gives an interesting overview of the current IDO1 inhibitors and their clinical trial results thus far.
IDO1 inhibitors have proven to be a promising therapeutic option that can be used in conjunction with chemotherapy and other cancer treatment methods. More research is needed on IDO1 and its intracellular interactions to minimize potential side effects and increase the efficacy of inhibitors.
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。